RxDoctor Payments Data

Ritche Chiu, MD

Nephrology · Hamilton, OHNPI 1952324659

Payments from drug & device makers

$1,728in general payments, 2019–2025

Across 35 payments — averaging $49.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$405
  • AstraZeneca$331
  • Bayer$133
  • Incyte Corporation$125
  • GSK$121
  • Teva Pharmaceuticals USA, Inc.$96
  • plus $517 from 10 others

What the payments were for

  • Food & beverage$1,59692%
  • Education$1328%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,728 in reported general payments places this provider in the 55th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$343,631
Medicare patients
702
Services billed
2,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide12$45,401
FarxigaDapagliflozin Propanediol26$22,996
JardianceEmpagliflozin24$22,617
Sevelamer Carbonate39$6,563
LokelmaSodium Zirconium Cyclosilicate13$5,762
Nifedipine ErNifedipine75$2,244
Calcium Acetate11$1,556
Labetalol Hcl65$1,201
Hydralazine Hcl151$1,158
Lisinopril168$1,013
Furosemide170$931
Spironolactone137$812
Losartan Potassium100$733
Chlorthalidone31$689
Torsemide50$664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$86$45,40112 claims
AstraZenecaFarxiga, Lokelma$331$28,75939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 nephrology providers in Ohio.

Other nephrology in Hamilton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →